The Limits of Personalized Medicine
By Timothy Caulfield,
The Atlantic
| 03. 16. 2016
Untitled Document
Personalized medicine—the idea that genetic testing can reveal a person’s unique risks for various illnesses, as well as the most effective treatments—has attracted a huge amount of attention over the past few years. While the concept includes promising approaches to things like cancer treatment, much of the focus has been on using genetic risk information to motivate healthy lifestyles. In his 2015 State of the Union address, President Obama suggested that future advances in biomedicine would provide the “personalized information we need to keep ourselves and our families healthier.” Francis Collins, the director of the National Institutes of Health, has suggested that personalized medicine “means taking better care of ourselves.”
In the context both men are describing—living healthier lifestyles to prevent chronic disease—the promise of personalized medicine lies in its ability to inspire behavior change. Having this genetic information isn’t inherently helpful; it’s what people do with the information that matters. But new research suggests that knowing one’s genetic risk isn’t enough to get people to quit smoking, eat better, or otherwise take actions to improve their health...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...